On the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: Structure and challenges

Journal of the European Academy of Dermatology and Venereology

Volumn 24, Issue 12, 2010, Pages 1458-1467

  Pathirana, D ^a   Nast, A ^a   Ormerod, A D ^b   Reytan, N ^a   Saiag, P ^c   Smith, C H ^d   Spuls, P ^e   Rzany, B ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

European evidence based guidelines; European S3 guidelines; psoriasis vulgaris; systemic therapy

Indexed keywords

ADALIMUMAB; ALEFACEPT; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; FOLIC ACID; FUMARIC ACID ETHYL ESTER; INFLIXIMAB; METHOTREXATE; RETINOID;

ARTICLE; EVIDENCE BASED PRACTICE; HUMAN; MEDICAL RESEARCH; PHOTOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS VULGARIS;

EUROPE; EVIDENCE-BASED MEDICINE; HUMANS; PRACTICE GUIDELINES AS TOPIC; PSORIASIS;

EID: 78449294515     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03671.x     Document Type: Article

References (12)

1. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Erarbeitung von Leitlinien für Diagnostik und Therapie, Methodische Empfehlungen ("Leitlinie für Leitlinien", Stand Dez. 2004). [WWW document] URL http://leitlinien.net (last accessed: 25 March 2010).
2. Nast A, Spuls PH, Ormerod AD, et al. A critical appraisal of evidence-based guidelines for the treatment of psoriasis vulgaris: 'AGREE-ing' on a common base for European evidence-based psoriasis treatment guidelines. J Eur Acad Dermatol Venereol 2009; 23: 782-787.
3. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005; 153: 486-497.
4. Van Zuiden Communications (Hrsg.). Richtlijn foto(chemo)therapie en systemische therapie bij ernstige chronische plaque psoriasis. 2003.
5. Spuls PI, Tuut MK, Van Everdingen JJ, De Rie MA,. [The practice guideline 'Photo(chemo)therapy and systemic therapy in severe chronic plaque-psoriasis']. Ned Tijdschr Geneeskd 2004; 148: 2121-2125.
6. Nast A, Kopp IB, Augustin M, et al. [S3-guidelines for the therapy of psoriasis vulgaris]. J Dtsch Dermatol Ges 2006; 4 (Suppl 2): S1-S126.
7. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris: supporting information. [WWW document] 2009. URL http://www3.interscience.wiley.com/journal/122577568/suppinfo (last accessed: 25 March 2010).
8. Pathirana D, Ormerod AD, Saiag P, et al. Erratum. J Acad Dermatol Venereol 2009; 24: 117-118.
9. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl 2): 1-70.
10. Abramson J, Starfield B,. The effect of conflict of interest on biomedical research and clinical practice guidelines: can we trust the evidence in evidence-based medicine? J Am Board Fam Pract 2005; 18: 414-418.
11. Choudhry NK, Stelfox HT, Detsky AS,. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002; 287: 612-617.
12. Holloway RG, Mooney CJ, Getchius TSD, et al. Invited article: conflicts of interest for authors of American Academy of Neurology clinical practice guidelines. Neurology 2008; 71: 57-63.